, above a certain threshold value is necessary for coagulation of mammalian biological fluids such as blood, blood plasma, and synovial fluid (1) (2) (3) (4) (5) . Less generally recognized is the fact that coagulation is inhibited by increased Ca 2ϩ activity (2) (3) (4) 6 ) . Thus, the coagulation reactions that occur in biological fluids require Ca 2ϩ activity within a certain range; this range is ϳ0.5-20 mmol/L. The physiological Ca 2ϩ activity of biological fluids is ϳ1.3 mmol/L. A motivation for the present study was the belief that the exact Ca 2ϩ activity within the range could be an important factor for the diagnostic performance of laboratory coagulation tests. The starting point for our investigation was the assumption that the physiological activity, 1.3 mmol/L, is the diagnostically most relevant condition. To allow precise regulation of Ca 2ϩ activity at physiological concentrations, the present study explores the possibility of buffering Ca 2ϩ at such concentrations. The main goals of the study were as follows: (a) to identify substances that buffer Ca 2ϩ activity in the physiological range, (b) to study the effects of the Ca 2ϩ -buffering substances on coagulation reactions, (c) to select the best buffer and design an activated partial thromboplastin time (APTT) procedure with final Ca 2ϩ buffered to near-physiological concentrations, and (d) to investigate whether such an APTT procedure would show signs of improved diagnostic efficacy in mild bleeding disorders. The fourth goal of the study was inspired by reports that some patients with mild clinical bleeding symptoms have APTT values within the reference interval (5, 7, 8 ) . 
Materials and Methods chemicals

patients
Patient plasmas from which all identity-revealing labels had been removed were obtained from the routine clinical chemistry laboratory at University Hospital, Linkö ping. Patient plasma was obtained by centrifugation for 20 min at 2500g after collecting 9 volumes of blood into 1 volume of 0.13 mol/L citrate.
procedures
APTT and prothrombin complex activity assays were performed in compliance with manufacturers' recommendations, using the following reagents: PTT Automate from Diagnostica Stago, and prothrombin complex reagent GHI 129 from Global Hemostasis Institute AB. The Ca 2ϩ concentration and pH were determined potentiometrically with an ICA 2 Ionized Calcium Analyzer (Radiometer). Coagulation assays were performed with nephelometric clot detection, using an ACL 300R from Instrumentation Laboratories. The Ca 2ϩ affinity, defined as the ligand complexation strength or chelating strength, of various water-soluble organic compounds was determined at ligand concentrations of 6 -50 mmol/L. The ligand was dissolved in 20 mmol/L HEPES to a concentration of ϳ100 mmol/L and neutralized to pH 7.3 with NaOH or HCl. One volume of 100 mmol/L ligand solution was mixed with one volume of 50 mmol/L CaCl 2 and further diluted with 150 mmol/L NaCl to obtain pHneutral solutions with one-half the stoichiometric amount of Ca 2ϩ relative to the ligand concentration. The Ca 2ϩ activity and pH were determined at 37°C, and the apparent dissociation constant was calculated. The Ca 2ϩ -buffering capacities of citrate and isocitrate were investigated in a fluid composed of one part thromboplastin, two parts plasma depleted of vitamin K-dependent coagulation factors, and one part CaCl 2 buffer mixed with two parts normal human plasma, prediluted 1:7 [the final reaction mixture of a prothrombin complex activity assay ( 
Results
A search for water-soluble ligands that could buffer Ca 2ϩ activity in the physiological range at ϳ1.3 mmol/L was conducted with the emphasis that the ligand must form a soluble Ca 2ϩ complex and display an apparent dissociation constant of 0.2-5 mmol/L at ligand concentrations of 5-50 mmol/L. The screening for ligands with desired properties included laboratory examination of methylmalonate, oxalate, iminodiacetate, dimethylmalonate, phthalate, diaminopurine, adenine, trans-aconitate, tricarballylate, citrate, and isocitrate. Apart from oxalate, which precipitated in the presence of Ca 2ϩ , all ligands except citrate and isocitrate showed apparent dissociation constants above 10 mmol/L at ligand concentrations of 5-50 mmol/L. Citrate exhibited apparent dissociation constants of 0.45-0.57 mmol/L, and isocitrate exhibited apparent dissociation constants of 3.9 -4.7 mmol/L. These two ligands were further investigated for use as Ca 2ϩ buffers in coagulation assays.
An initial investigation was performed to determine whether citrate and isocitrate had an effect on coagulation reactions not related to a reduction of Ca 2ϩ activity. Coagulation time was determined in a fluid composed of blood plasma, thromboplastin, various concentrations of CaCl 2 , and 0, 5, 10, or 20 mmol/L citrate or isocitrate. Citrate and isocitrate inhibited coagulation reactions at all Ca 2ϩ activity values in the coagulation-permissive range, as shown in Figs. 1 and 2 . On a molar basis, this inhibitory effect was about twice as large for citrate as for isocitrate, which was readily demonstrated by plotting the coagulation time at any Ca 2ϩ activity against the ligand concentration. This inhibition limited the concentration of citrate Clinical Chemistry 45, No. 8, 1999 and isocitrate that could be used for buffering Ca 2ϩ in a coagulation test. At concentrations Ͼ20 mmol/L, the inhibitory effect was predominant. In addition, it appeared that a smaller reduction in Ca 2ϩ activity was required to achieve anticoagulation at increased concentrations of citrate or isocitrate, which may indicate that sufficiently increased concentrations of citrate or isocitrate may block coagulation of biological fluids at physiological Ca 2ϩ activities. The data in Figs. 1 and 2 also allowed an estimate of Ca 2ϩ -buffering capacity at various concentrations of Ca 2ϩ activity because the difference in added CaCl 2 and the difference in Ca 2ϩ activity between any two experimental points were known. Using adjacent data points, the Ca 2ϩ -buffering capacity of the fluid with 0, 5, 10, and 20 mmol/L citrate or isocitrate was estimated for Ca 2ϩ activity in the range 1-5 mmol/L. The results are shown in the insets of Fig. 3 . The increased Ca 2ϩ -buffering capacity was assumed to be proportional to the ligand concentration, and the data at 5 and 20 mmol/L were used in estimating the increased Ca 2ϩ -buffering capacity at 10 mmol/L. The mean increased Ca 2ϩ -buffering capacity and SD from the three estimates for both citrate and isocitrate are shown in Fig. 3 . Both citrate and isocitrate significantly increased the Ca 2ϩ -buffering capacity of the solutions in the Ca 2ϩ activity range studied (P Ͻ0.0007 and P Ͻ0.0009, respectively, Wilcoxon matched-pairs test). Isocitrate tended to give a greater increase than citrate (P Ͻ0.09), on average, 32% greater. This additional increase notwithstanding, isocitrate was a better Ca 2ϩ buffer for coagulation assays because it could be present at twice the concentration without causing excessive inhibition. Thus, compared with citrate, isocitrate yielded at least twice as much increased Ca 2ϩ -buffering capacity in the Ca 2ϩ activity range 1-5 mmol/L.
Isocitrate was chosen to modify an APTT procedure with the aim to adjust the Ca 2ϩ activity to near-physiological concentrations. F, no added isocitrate; E, 5 mmol/L added isocitrate; , 10 mmol/L added isocitrate; ƒ, 20 mmol/L added isocitrate. Ca 2ϩ activity was determined potentiometrically. 
Discussion
This study investigated 11 Ca 2ϩ ligands for their utility as buffers for Ca 2ϩ activity in the physiological range for possible application in laboratory diagnostic coagulation procedures. Only two of the ligands, citrate and isocitrate, formed Ca 2ϩ complexes with apparent dissociation constants between 0.5 and 5 mmol/L and thus were suitable as Ca 2ϩ -buffering agents in the physiological Ca 2ϩ activity range. Citrate and isocitrate were further investigated regarding their effect on coagulation procedures and their ability to increase Ca 2ϩ -buffering capacity in the final reaction mixture. The study provided two reasons to prefer isocitrate to citrate: isocitrate was less inhibitory in coagulation procedures and hence could be used at higher concentrations, and isocitrate was more efficient in increasing the Ca 2ϩ -buffering capacity of coagulation procedures.
The study clearly demonstrated that citrate and isocitrate have an inhibitory effect on coagulation reactions that is independent of Ca 2ϩ activity. Citrate and isocitrate thus may prevent coagulation of a biological fluid with Ca 2ϩ activity retained at physiological concentrations.
A commonly used APTT procedure was modified by the addition of isocitrate to a final concentration of 10 mmol/L. Analysis of 22 healthy individuals established reference intervals for the two procedures. Analysis of 120 randomly selected hospital laboratory patient plasma samples with both the modified and the original APTT procedures revealed intriguing aspects related to diagnostic power. In the modified APTT, the patient samples were abnormal both to a higher degree (P Ͻ0.005) and to a higher frequency (P Ͻ0.07). These results are interesting in the light of known discrepancies between clinical and laboratory findings. A good fraction of patients that display mild clinical bleeding may test normal with APTT (5, 7, 8 ) . The present study indicates that APTT procedures in which the Ca 2ϩ activity is in the near-physiological range may have a greater diagnostic power than those with higher Ca 2ϩ activity. It is not immediately obvious why the widely used commercial APTT procedure, referred to above as the original APTT, displayed a Ca 2ϩ activity of 2.7 mmol/L and not the physiological activity of 1.3 mmol/L. APTT is considered a global coagulation procedure with conditions that are, as far as practically possible, physiological at 37°C, pH 7.3, and an ionic strength 150 mmol/L. One would then expect that the Ca 2ϩ activity should be nearly 1.3 mmol/L, which is clearly not the case. It has been reported that APTT becomes more sensitive to heparin at higher Ca 2ϩ activities (11 ) . The rational for the hyperphysiological Ca 2ϩ activity could be that the manufacturer has aimed for high heparin sensitivity and has been unaware of the risk for reduced diagnostic power in identifying bleeding conditions. Another possible explanation is that the APTT procedure has a built-in safety margin to hypophysiological Ca 2ϩ activities because these are generally recognized as being detrimental for coagulation reactions.
In conclusion, the present study indicates a possibility to increase the diagnostic power of global coagulation assays in mild hemophilia. This increased power may be obtained by buffering the final Ca 2ϩ activity to near physi- ological concentrations. The study also points to the possibility of more gentle anticoagulation of biological fluids in which the final Ca 2ϩ activity is only moderately reduced. The study identifies isocitrate as a substance that can function as a Ca 2ϩ buffer in coagulation assays and as an anticoagulant in biological fluids.
